Emily Estrada on Muck Rack

Emily Estrada

Verified
Washington, D.C.
As seen in: HMP Global Learning Network, Oncology Learning Network, The Clinical Advisor, Psychiatry Advisor, Cancer Therapy Advisor, Renal & Urology News, Neurology Advisor, Infectious Disease Advisor, Endocrinology Advisor, Dermatology Advisor, Pulmonology Advisor and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Emily

Contact Emily, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Serplulimab Plus Chemotherapy Shows Sustained Survival Benefit in Extensive-Stage Small Cell Lung Cancer

|
By Emily Estrada Verified
| Oncology Learning Network Verified
Clinical Summary: Design/Population: This double-blind, phase 3 trial evaluated serplulimab plus carboplatin and etoposide in patients with previously untreated extensive-stage small cell lung cancer. Key Outcomes: At extended follow-up, serplulimab plus chemotherapy significantly improved median overall survival and increased overall survival rates, with no new safety signals and favorable patient-reported outcomes.
Open in Who Shared Issue with article?

Real-World Study Confirms Survival Benefit of First-Line Chemoimmunotherapy in Extensive-Stage Small Cell Lung Cancer

|
By Emily Estrada Verified
| Oncology Learning Network Verified
Clinical Summary: Design/Population: This retrospective real-world study evaluated first-line chemoimmunotherapy versus platinum-based chemotherapy and non-platinum chemotherapy in patients with newly diagnosed extensive-stage small cell lung cancer. Key Outcomes: Chemoimmunotherapy significantly improved overall and progression-free survival compared with platinum-etoposide chemotherapy.
Open in Who Shared Issue with article?

Durvalumab Plus Anlotinib Maintenance Improves PFS in Extensive-Stage Small Cell Lung Cancer

|
By Emily Estrada Verified
| Oncology Learning Network Verified
Clinical Summary: Design/Population: This phase 2 trial evaluated durvalumab plus anlotinib vs durvalumab alone as maintenance therapy after first-line durvalumab plus platinum-etoposide chemotherapy in patients with extensive-stage small cell lung cancer. Key Outcomes: Maintenance therapy with durvalumab plus anlotinib significantly prolonged progression-free survival compared with durvalumab alone, with a manageable safety profile.
Open in Who Shared Issue with article?
See all 500 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified